Immunotherapy
Guangzhou, Guangdong, 510060, China
NCT Number: NCT01749865
This is a randomized controlled study. About 200 patients with hepatocellular carcinoma who underwent radical resection will be included. The patients will be randomized to group A (receive CIK treatment) or group B (just regularly follow up) without any anti-cancer treatment after resection of HCC, and the randomize ratio will be 1:1.
Looking for future studies?
Notify Me18 year–100 year
All sexes
Interventional
Phase 3
Guangzhou, Guangdong, 510060, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Definition of radical resection in this study:
Exclusion criteria
Prior use of any anti-cancer treatment for HCC, eg. chemotherapy, radiotherapy. Antiviral treatment is allowed.
Cytokine-Induced Killer Cells treatment for 4 cycles
Other names: CIK
Time frame: 5-year
To evaluate efficacy of CIK treatment as an adjuvant therapy in patients with hepatocellular carcinoma (HCC) who underwent radical resection.
Time frame: 5 year
Disease Free Survival
Time frame: 5 years
To evaluate safety of CIK treatment as an adjuvant therapy in patients with hepatocellular carcinoma (HCC) who underwent radical resection.
Sun Yat-sen University
Other
A Randomized Controlled Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients With Hepatocellular Carcinoma Who Underwent Radical Resection
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01171651
Adenocarcinoma, Carcinoma
Busan, South Korea
View Trial DetailsNCT04962958
Adenocarcinoma, Antimetabolites
Guangzhou, Guangdong, China
View Trial DetailsNCT04102098
Adenocarcinoma, Carcinoma
Los Angeles, California, United States
View Trial DetailsNCT00554372
Adenocarcinoma, Carcinoma
La Jolla, California, United States
View Trial Details